Early prediction of clinical response to anti|TNF treatment using ...

Prediction of Treatment Response to Chemoimmunotherapy

Another study reveals that among patients with PD-L1 TPS greater than or equal to 50% in their NSCLC treated with first-line ICI, clinical outcomes are improved ...

Effectiveness, predictive response factors, and safety of anti-tumor ...

Patients who displayed good adherence prior to the anti-TNF treatment and were treated with etanercept or with increasing doses of infliximab ...

Optimizing anti-TNF treatment in inflammatory bowel disease

At 1 year, 62% of the patients had maintained response and 53% had maintained remission with repeated infliximab infusions of 10 mg/kg, whereas only 37% were ...

Clinical outcomes and predictors of response for adalimumab in ...

Prior anti-TNF-α therapy has been reported to have controversial effects on clinical outcomes of ADA in patients with UC. The ULTRA-2 and ULTRA- ...

Rheumatoid Arthritis : Anti-TNF Therapy for the Treatment of RA

Human Clinical Trials ... Because the safety of the TNF inhibitors in humans was unknown, early trials in RA targeted patients with severe, longstanding disease ...

Prospective Validation of CD-62L (L-Selectin) as Marker of Durable ...

The development of biomarkers to guide management of anti–tumor necrosis factor (TNF) agents in patients with inflammatory bowel disease (IBD) is an unmet need.

Prediction of Relapse After Anti–Tumor Necrosis Factor Cessation in ...

Individual participant data were requested for luminal CD patients and anti-TNF treatment duration of 6 months or longer. The discriminative ...

Predictors of anti-TNF treatment failure in anti-TNF-naive patients ...

... with and predictive of anti-TNF failure in the first year of treatment. ... clinical response in patients with ulcerative colitis. Int J ...

Predicting Clinical Response to Monoclonal TNF Inhibitors in ...

... Anti-TNF Drug to Treat Rheumatoid Arthritis in Patients With Insufficient Response to a First Anti-TNF Drug: A Randomized Clinical Trial.

Clinical Utility of Random Anti–Tumor Necrosis Factor Drug–Level ...

and/or drug non-trough levels predict the long- term treatment response in a large cohort of patients with rheumatoid arthritis (RA) treated with adalimu- mab ...

MolDX: Molecular Biomarker Testing to Guide Targeted Therapy ...

... response to therapy above that which was obtained by available clinical ... Predicting response to anti-tnf treatment in rheumatoid arthritis patients.

Prediction of Response to Immune Checkpoint Inhibitor Therapy ...

One patient received nivolumab (anti–PD-1) on a clinical trial in the first-line setting. Treatment Response. Tumor responses were measured by ...

Clinical Validation of a Blood-Based Predictive Test for Stratification ...

Results: Data from two patient cohorts (n=58 and n=143) were used to build a drug response biomarker panel that predicts nonresponse to anti-TNF ...

Examining clinical and genetic factors that impact response to anti ...

Approved in 1998 for use in treating Crohn's disease and subsequently in 2005 for treating ulcerative colitis, anti-tumor necrosis factor ...

In Crohn's Disease, Early Anti-TNF Levels May Be Crucial - Medscape

Among patients with Crohn's disease, anti-TNF therapy failed to achieve remission at 3 years, and high drug concentrations early in ...

A Personalized Approach to Biological Therapy Using Prediction of ...

Based on the treatment algorithm 80 patients would have been recommended for anti-TNF treatment, 8 for rituximab, 13 for another biological treatment (other ...

Can we predict which patients with psoriatic arthritis will respond to ...

All patients will be treated with a biologic drug (TNF inhibitors (adalimumab) or IL-17A inhibitors (secukinumab) in keeping with routine clinical practice.

Machine Learning Prediction of Treatment Response to Biological ...

This study aims to leverage machine learning to predict both initial response at 6 months and sustained response at 12 months using baseline clinical data.

Long-term clinical and real-world experience with Crohn's disease ...

Although anti-tumor necrosis factor (TNF)-α agents are important therapeutic drugs for inflammatory bowel diseases, the incidence of secondary loss of response ...

Cytokine responses in nonlesional psoriatic skin as clinical predictor ...

information regarding how each patient's characteristics associate with treatment outcomes is urgently needed. Previous studies using gene ...